Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iGlarLixi versus premixed insulin in adults with type 2 diabetes inadequately controlled on basal insulin plus oral antidiabetic drugs
2017-003370-13Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine + lixisenatide and Insulin aspart + insulin aspart protamine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in glycated hemoglobin. Started Jun 2018; status: completed.
02
Drugs
insulin glargine + lixisenatideInsulin aspart + insulin aspart protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-003370-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003370-13.